# Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients

> **NCT01131637** · PHASE3 · TERMINATED · sponsor: **Zensun Sci. & Tech. Co., Ltd.** · enrollment: 331 (actual)

## Conditions studied

- Chronic Heart Failure

## Interventions

- **DRUG:** rhNRG-1
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01131637
- **Lead sponsor:** Zensun Sci. & Tech. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04
- **Primary completion:** 2012-06
- **Final completion:** 2012-08
- **Target enrollment:** 331 (ACTUAL)
- **Why stopped:** Sponsor has designed another study to replace the current study
- **Last updated:** 2017-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01131637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01131637, "Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01131637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*